EDA-Fibronectin Originating from Osteoblasts Inhibits the Immune Response against Cancer

PLoS Biology

Volumn 14, Issue 9, 2016, Pages

  Rossnagl, Stephanie ^a,b   Altrock, Eva ^a,b   Sens, Carla ^a,b   Kraft, Sabrina ^a,b   Rau, Katrin ^a,b   Milsom, Michael D ^c,d   Giese, Thomas ^b   Samstag, Yvonne ^b   Nakchbandi, Inaam A ^a,b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Heidelberg Institute for Stem Cell Technology and Experimental Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGINASE 1; CELL SURFACE RECEPTOR; EXTRA DOMAIN A FIBRONECTIN; FIBRONECTIN; ISOPROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER MODEL; CELL FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SYNTHESIS; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; LIVER FIBROSIS; MOUSE; MOUSE MODEL; NEWBORN; NONHUMAN; OSTEOBLAST; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; TISSUE INJURY; TUMOR IMMUNITY; WOUND HEALING;

EID: 84991758854     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002562     Document Type: Article

References (69)

1. Yin T, Li L, The stem cell niches in bone. The Journal of clinical investigation. 2006;116(5):1195–201. Epub 2006/05/04. doi: 10.1172/JCI2856816670760; PubMed Central PMCID: PMC1451221.
2. Boulais PE, Frenette PS, Making sense of hematopoietic stem cell niches. Blood. 2015;125(17):2621–9. Epub 2015/03/13. doi: 10.1182/blood-2014-09-57019225762174; PubMed Central PMCID: PMC4408288.
3. Askmyr M, Sims NA, Martin TJ, Purton LE, What is the true nature of the osteoblastic hematopoietic stem cell niche?Trends in endocrinology and metabolism: TEM. 2009;20(6):303–9. Epub 2009/07/15. doi: 10.1016/j.tem.2009.03.00419595609.
4. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–6. Epub 2003/10/24. [pii] 14574413.
5. Taichman RS, Reilly MJ, Emerson SG, Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood. 1996;87(2):518–24. Epub 1996/01/15. 8555473.
6. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL, Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood. 2004;103(9):3258–64. Epub 2004/01/17. doi: 10.1182/blood-2003-11-4011 2003-11-4011 [pii]. 14726388.
7. Taichman RS, Emerson SG, The role of osteoblasts in the hematopoietic microenvironment. Stem Cells. 1998;16(1):7–15. Epub 1998/02/25. doi: 10.1002/stem.1600079474743.
8. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K, Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. The Journal of clinical endocrinology and metabolism. 2002;87(11):4946–51. Epub 2002/11/05. 12414855.
9. Nakchbandi IA, Mitnick MA, Masiukiewicz US, Sun BH, Insogna KL, IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology. 2001;142(9):3850–6. Epub 2001/08/23. 11517162.
10. Peters M, Muller AM, Rose-John S, Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood. 1998;92(10):3495–504. Epub 1998/11/10. 9808540.
11. Cho SW, Pirih FQ, Koh AJ, Michalski M, Eber MR, Ritchie K, et al. The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone. The Journal of biological chemistry. 2013;288(10):6814–25. Epub 2013/01/09. doi: 10.1074/jbc.M112.39336323297399; PubMed Central PMCID: PMC3591592.
12. Verfaillie CM, McCarthy JB, McGlave PB, Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med. 1991;174(3):693–703. Epub 1991/09/01. 1875168; PubMed Central PMCID: PMC2118931.
13. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med. 2001;7(3):324–30. Epub 2001/03/07. doi: 10.1038/85471 85471 [pii]. 11231631.
14. Bentmann A, Kawelke N, Moss D, Zentgraf H, Bala Y, Berger I, et al. Circulating fibronectin affects bone matrix, whereas osteoblast fibronectin modulates osteoblast function. J Bone Miner Res. 2010;25(4):706–15. Epub 2009/10/14. doi: 10.1359/jbmr.09101119821765.
15. Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S, et al. Fibronectin regulates calvarial osteoblast differentiation. Journal of cell science. 1996;109 (Pt 6):1369–80. 8799825.
16. von Au A, Vasel M, Kraft S, Sens C, Hackl N, Marx A, et al. Circulating fibronectin controls tumor growth. Neoplasia. 2013;15(8):925–38. Epub 2013/08/03. 23908593; PubMed Central PMCID: PMC3730044.
17. Gothot A, Giet O, Huygen S, Beguin Y, Binding and migration across fibronectin and VCAM-1 of cycling hematopoietic progenitor cells. Leukemia & lymphoma. 2003;44(8):1379–83. Epub 2003/09/04. 12952232.
18. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7. Epub 2005/12/13. nature04186 [pii] doi: 10.1038/nature0418616341007.
19. Yokota T, Oritani K, Mitsui H, Aoyama K, Ishikawa J, Sugahara H, et al. Growth-supporting activities of fibronectin on hematopoietic stem/progenitor cells in vitro and in vivo: structural requirement for fibronectin activities of CS1 and cell-binding domains. Blood. 1998;91(9):3263–72. Epub 1998/05/23. 9558382.
20. Dao MA, Nolta JA, Cytokine and integrin stimulation synergize to promote higher levels of GATA-2, c-myb, and CD34 protein in primary human hematopoietic progenitors from bone marrow. Blood. 2007;109(6):2373–9. Epub 2006/11/11. doi: 10.1182/blood-2006-05-02603917095623; PubMed Central PMCID: PMC1852192.
21. Leiss M, Beckmann K, Giros A, Costell M, Fassler R, The role of integrin binding sites in fibronectin matrix assembly in vivo. Curr Opin Cell Biol. 2008;20(5):502–7. Epub 2008/07/01. S0955-0674(08)00111-7 [pii] doi: 10.1016/j.ceb.2008.06.00118586094.
22. Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K, Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol. 1997;139(1):295–307. 9314547.
23. Manabe R, Ohe N, Sekiguchi K, Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. The Journal of biological chemistry. 1999;274(9):5919–24. Epub 1999/02/20. 10026216.
24. Rose DM, Han J, Ginsberg MH, Alpha4 integrins and the immune response. Immunological reviews. 2002;186:118–24. Epub 2002/09/18. 12234367.
25. Bonig H, Watts KL, Chang KH, Kiem HP, Papayannopoulou T, Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells. 2009;27(4):836–7. Epub 2009/04/08. doi: 10.1002/stem.919350684; PubMed Central PMCID: PMC2892056.
26. DeNucci CC, Pagan AJ, Mitchell JS, Shimizu Y, Control of alpha4beta7 integrin expression and CD4 T cell homing by the beta1 integrin subunit. J Immunol. 2010;184(5):2458–67. Epub 2010/02/02. jimmunol.0902407 [pii] doi: 10.4049/jimmunol.090240720118278; PubMed Central PMCID: PMC2824783.
27. Kumar S, Ponnazhagan S, Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. FASEB J. 2007;21(14):3917–27. Epub 2007/07/12. doi: 10.1096/fj.07-8275com17622670.
28. Ogawa M, Kizumoto M, Nishikawa S, Fujimoto T, Kodama H, Nishikawa SI, Expression of alpha4-integrin defines the earliest precursor of hematopoietic cell lineage diverged from endothelial cells. Blood. 1999;93(4):1168–77. Epub 1999/02/09. 9949159.
29. Arroyo AG, Yang JT, Rayburn H, Hynes RO, Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity. 1999;11(5):555–66. Epub 1999/12/11. 10591181.
30. Kapur R, Cooper R, Zhang L, Williams DA, Cross-talk between alpha(4)beta(1)/alpha(5)beta(1) and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signaling pathways. Blood. 2001;97(7):1975–81. Epub 2001/03/27. 11264161.
31. Tanaka R, Owaki T, Kamiya S, Matsunaga T, Shimoda K, Kodama H, et al. VLA-5-mediated adhesion to fibronectin accelerates hemin-stimulated erythroid differentiation of K562 cells through induction of VLA-4 expression. J Biol Chem. 2009;284(30):19817–25. Epub 2009/05/23. doi: 10.1074/jbc.M109.00986019460753; PubMed Central PMCID: PMC2740407.
32. Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF, CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol. 2010;185(1):203–10. Epub 2010/06/08. doi: 10.4049/jimmunol.090357320525890.
33. Kondo M, Weissman IL, Akashi K, Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell. 1997;91(5):661–72. Epub 1997/12/11. 9393859.
34. Challen GA, Boles N, Lin KK, Goodell MA, Mouse hematopoietic stem cell identification and analysis. Cytometry Part A: the journal of the International Society for Analytical Cytology. 2009;75(1):14–24. Epub 2008/11/22. doi: 10.1002/cyto.a.2067419023891; PubMed Central PMCID: PMC2640229.
35. Gabrilovich DI, Nagaraj S, Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74. Epub 2009/02/07. doi: 10.1038/nri250619197294; PubMed Central PMCID: PMC2828349.
36. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol. 2005;175(12):8200–8. Epub 2005/12/13. 175/12/8200 [pii]. 16339559.
37. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 2000;96(12):3838–46. Epub 2000/11/23. 11090068; PubMed Central PMCID: PMC2734459.
38. Capietto AH, Kim S, Sanford DE, Linehan DC, Hikida M, Kumosaki T, et al. Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J Exp Med. 2013;210(11):2257–71. Epub 2013/10/16. doi: 10.1084/jem.2013028124127488; PubMed Central PMCID: PMC3804931.
39. Weilbaecher KN, Guise TA, McCauley LK, Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–25. Epub 2011/05/20. doi: 10.1038/nrc305521593787; PubMed Central PMCID: PMC3666847.
40. Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM, et al. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol. 2000;165(12):6723–30. Epub 2000/12/20. 11120790.
41. Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai N, Kapoor V, et al. CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology. 2016;5(1):e1061175. Epub 2016/03/05. doi: 10.1080/2162402X.2015.106117526942073; PubMed Central PMCID: PMC4760327.
42. Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, et al. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Current cancer drug targets. 2011;11(6):734–51. Epub 2011/05/24. 21599634; PubMed Central PMCID: PMC3670669.
43. Munder M, Arginase: an emerging key player in the mammalian immune system. British journal of pharmacology. 2009;158(3):638–51. Epub 2009/09/22. doi: 10.1111/j.1476-5381.2009.00291.x19764983; PubMed Central PMCID: PMC2765586.
44. Kawelke N, Vasel M, Sens C, von Au A, Dooley S, Nakchbandi IA, Fibronectin Protects from Excessive Liver Fibrosis by Modulating the Availability of and Responsiveness of Stellate Cells to Active TGF-beta. PLoS ONE. 2011;6(11):e28181. Epub 2011/12/06. doi: 10.1371/journal.pone.0028181 PONE-D-11-09211 [pii]. 22140539; PubMed Central PMCID: PMC3225392.
45. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(46):E3186–95. Epub 2012/10/27. doi: 10.1073/pnas.111996410923100531; PubMed Central PMCID: PMC3503234.
46. Schofield KP, Humphries MJ, de Wynter E, Testa N, Gallagher JT, The effect of alpha4 beta1-integrin binding sequences of fibronectin on growth of cells from human hematopoietic progenitors. Blood. 1998;91(9):3230–8. Epub 1998/05/23. 9558378.
47. Yanai N, Sekine C, Yagita H, Obinata M, Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood. 1994;83(10):2844–50. Epub 1994/05/15. 7514048.
48. Yoshida H, Nishiura T, Karasuno T, Matsumura I, Ishikawa J, Yoshimura M, et al. Effect of the interaction between fibronectin and VLA-4 on the proliferation of human B cells, especially a novel human B-cell line, OPM-3. Br J Haematol. 1998;103(3):804–12. Epub 1998/12/19. 9858236.
49. Cheng L, Wang J, Li X, Xing Q, Du P, Su L, et al. Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice. PLoS ONE. 2011;6(3):e17631. Epub 2011/03/12. doi: 10.1371/journal.pone.001763121394214; PubMed Central PMCID: PMC3048877.
50. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L, Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J Biol Chem. 2011;286(26):23591–9. Epub 2011/05/20. doi: 10.1074/jbc.M111.23712321592961; PubMed Central PMCID: PMC3123122.
51. Nagaraj S, Youn JI, Gabrilovich DI, Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol. 2013;191(1):17–23. Epub 2013/06/26. doi: 10.4049/jimmunol.130065423794702; PubMed Central PMCID: PMC3694485.
52. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, et al. Attenuated liver fibrosis in the absence of B cells. J Clin Invest. 2005;115(11):3072–82. Epub 2005/11/09. doi: 10.1172/JCI2479816276416; PubMed Central PMCID: PMC1265860.
53. Smith CI, Cooksley WG, Powell LW, Cell-mediated immunity to liver antigen in toxic liver injury. II. Role in pathogenesis of liver damage. Clin Exp Immunol. 1980;39(3):618–25. Epub 1980/03/01. 6966549; PubMed Central PMCID: PMC1538134.
54. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010;36(8):615–20. Epub 2010/05/19. doi: 10.1016/j.ctrv.2010.04.00320478658; PubMed Central PMCID: PMC3047387.
55. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201(8):1257–68. Epub 2005/04/13. doi: 10.1084/jem.2004202815824085; PubMed Central PMCID: PMC2213151.
56. Feldmeyer N, Wabnitz G, Leicht S, Luckner-Minden C, Schiller M, Franz T, et al. Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes. International immunology. 2012;24(5):303–13. Epub 2012/02/22. doi: 10.1093/intimm/dxs00422345165.
57. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM, Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A. 2010;107(18):8363–8. Epub 2010/04/21. 0911378107 [pii] doi: 10.1073/pnas.091137810720404138; PubMed Central PMCID: PMC2889597.
58. Parkos CA, Delp C, Arnaout MA, Madara JL, Neutrophil migration across a cultured intestinal epithelium. Dependence on a CD11b/CD18-mediated event and enhanced efficiency in physiological direction. J Clin Invest. 1991;88(5):1605–12. Epub 1991/11/01. doi: 10.1172/JCI1154731682344; PubMed Central PMCID: PMC295682.
59. Rybak JN, Roesli C, Kaspar M, Villa A, Neri D, The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer research. 2007;67(22):10948–57. Epub 2007/11/17. 67/22/10948 [pii] doi: 10.1158/0008-5472.CAN-07-143618006840.
60. Han Z, Zhou Z, Shi X, Wang J, Wu X, Sun D, et al. EDB Fibronectin Specific Peptide for Prostate Cancer Targeting. Bioconjugate chemistry. 2015;26(5):830–8. Epub 2015/04/08. doi: 10.1021/acs.bioconjchem.5b0017825848940.
61. Almokadem S, Belani CP, Volociximab in cancer. Expert opinion on biological therapy. 2012;12(2):251–7. Epub 2011/12/24. doi: 10.1517/14712598.2012.64698522192080.
62. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839–49. Epub 2004/08/18. doi: 10.1158/0008-5472.CAN-04-046515313928.
63. Rossnagl S, von Au A, Vasel M, Cecchini AG, Nakchbandi IA, Blood clot formation does not affect metastasis formation or tumor growth in a murine model of breast cancer. PLoS ONE. 2014;9(4):e94922. Epub 2014/04/18. doi: 10.1371/journal.pone.009492224740307; PubMed Central PMCID: PMC3989235.
64. Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka DB, Reyes A, Wang Q, et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 2014;15(4):507–22. Epub 2014/08/28. doi: 10.1016/j.stem.2014.07.00525158935.
65. Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res. 2008;23(8):1278–86. 18348696. doi: 10.1359/jbmr.080313
66. Kraft S, Klemis V, Sens C, Lenhard T, Jacobi C, Samstag Y, et al. Identification and characterization of a unique role for EDB fibronectin in phagocytosis. J Mol Med (Berl). 2015. Epub 2015/12/08. doi: 10.1007/s00109-015-1373-026637426.
67. Kapanadze T, Medina-Echeverz J, Gamrekelashvili J, Weiss JM, Wiltrout RH, Kapoor V, et al. Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. European journal of immunology. 2015;45(4):1148–58. Epub 2015/01/24. doi: 10.1002/eji.20144509325616156; PubMed Central PMCID: PMC4425346.
68. Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, et al. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol. 2010;45(3):349–56. Epub 2009/12/19. doi: 10.3109/0036552090349060620017652.
69. Altrock E, Sens C, Wuerfel C, Vasel M, Kawelke N, Dooley S, et al. Inhibition of fibronectin deposition improves experimental liver fibrosis. Journal of hepatology. 2015;62(3):625–33. Epub 2014/06/20. doi: 10.1016/j.jhep.2014.06.01024946284.